News | February 25, 2025
Biocon Biologics launches Yesintek Biosimilar to Stelara in US
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
ALS patients experience neuroinflammation and rapid neurodegeneration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Subscribe To Our Newsletter & Stay Updated
